Article · Wikipedia archive · Last revised Jul 23, 2026

2C-iP

2C-iP, also known as 4-isopropyl-2,5-dimethoxyphenethylamine or as Jelena or Momento, is a psychedelic drug of the phenethylamine and 2C families. It is taken orally. The drug was first described by 2011 and was encountered as a novel designer drug by 2018.

Last revised
Jul 23, 2026
Read time
≈ 2 min
Length
443 w
Citations
20
Source
Wikipedia ↗
2C-iP
Clinical data
Other names4-Isopropyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-isopropylphenethylamine; Jelena; Momento
Routes of
administration		Oral1
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Pharmacokinetic data
Duration of action8–12 hours1
Identifiers
  • 2-[2,5-dimethoxy-4-(propan-2-yl)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO2
Molar mass223.316 g·mol−1
3D model (JSmol)
  • COC1=C(C=C(C(=C1)C(C)C)OC)CCN
  • InChI=1S/C13H21NO2/c1-9(2)11-8-12(15-3)10(5-6-14)7-13(11)16-4/h7-9H,5-6,14H2,1-4H3
  • Key:XUGPCRRUMVWELT-UHFFFAOYSA-N

2C-iP, also known as 4-isopropyl-2,5-dimethoxyphenethylamine or as Jelena or Momento, is a psychedelic drug of the phenethylamine and 2C families.123 It is taken orally.1 The drug was first described by 20113 and was encountered as a novel designer drug by 2018.2

Use and effects

2C-iP's dose is 8 to 25 mg orally and its duration is 8 to 12 hours.1 It is said that careful dose titration is necessary to avoid overdose.1 The drug is said to produce a strong sense of heightened awareness of the present moment, resulting in the nickname "Momento", among other effects.1

Interactions

Pharmacology

Pharmacodynamics

2C-iP shows affinity for the serotonin 5-HT2 receptors, including for the serotonin 5-HT2A receptor.1

Chemistry

Analogues

Analogues of 2C-iP include 2C-P, 2C-cP, 2C-iBu, 2C-tBu, 2C-D, 2C-E, 2C-T-4, and DOiP, among others.412

History

2C-iP was first described in the scientific literature by Dmitri Ger and colleagues by 2011.3 It was encountered as a novel designer drug in Sweden in 2018.2

Society and culture

Canada

As of October 31, 2016, 2C-iP is a controlled substance (Schedule III) in Canada.5

United States

2C-iP is not an explicitly controlled substance in the United States.6 However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. In addition, it may be considered scheduled as an isomer of 2C-P.6

See also

See also

References

References

  1. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. "2C-IP". АИПСИН (in Russian). Retrieved 1 January 2026.
  3. Ger A, Ger D (1 March 2011). "Triple Goddess of the Night". British Neuroscience Association Bulletin. Archived from the original on 19 February 2014. Retrieved 16 July 2015.
  4. Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  5. "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Controlled Drugs and Substances Act. Government of Canada. 15 April 2016.
  6. Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
External links